{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["BBT-176"]],"indication":"advanced NSCLC with progression after EGFR TKI treatment","name":"NCT04820023","nct_id":"NCT04820023","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct04820023. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"BBT-176: 20mg, Orally, Once daily (QD)","label":"20mg QD","type":"EXPERIMENTAL"},{"description":"BBT-176: 80mg, Orally, QD","label":"80mg QD","type":"EXPERIMENTAL"},{"description":"BBT-176: 160mg, Orally, QD","label":"160mg QD","type":"EXPERIMENTAL"},{"description":"BBT-176: 320mg, Orally, QD","label":"320mg QD","type":"EXPERIMENTAL"},{"description":"BBT-176: 480mg, Orally, QD","label":"480mg QD","type":"EXPERIMENTAL"},{"description":"BBT-176: 600mg, Orally, QD","label":"600mg QD","type":"EXPERIMENTAL"},{"description":"BBT-176: 160mg, Orally, Twice daily (BID)","label":"160mg, BID","type":"EXPERIMENTAL"},{"description":"BBT-176: 200mg, Orally, BID","label":"200mg, BID","type":"EXPERIMENTAL"},{"description":"BBT-176: 240mg, Orally, BID","label":"240mg, BID","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2023-11-29","type":"ACTUAL"},"conditions":["NSCLC"],"enrollment":{"count":45,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"BBT-176, QD","otherNames":[],"type":"DRUG"},{"name":"BBT-176, BID","otherNames":[],"type":"DRUG"}],"last_update":"2025-06-06","lead_sponsor":"Bridge Biotherapeutics, Inc.","official_title":"A Phase 1/2, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of BBT-176 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Progressed Following Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Agent","overall_status":"TERMINATED","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2023-11-29","type":"ACTUAL"},"primary_outcomes":[{"measure":"(Part 1) Incidence of Adverse Events and Clinical Laboratory Abnormalities Defined as Dose-limiting Toxicities (DLTs)","timeFrame":"21 days from the first dosing"},{"measure":"(Part 2) Objective Response Rate (ORR)","timeFrame":"Every 6 weeks"}],"references":[{"citation":"Lim SM, Fujino T, Kim C, Lee G, Lee YH, Kim DW, Ahn JS, Mitsudomi T, Jin T, Lee SY. BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non-Small Cell Lung Cancer. Clin Cancer Res. 2023 Aug 15;29(16):3004-3016. doi: 10.1158/1078-0432.CCR-22-3901.","pmid":"37249619","type":"DERIVED"}],"start_date":{"date":"2021-04-02","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment","url":"https://clinicaltrials.gov/study/NCT04820023"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct04820023"}